| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of Pathology [M. G., M. S., C. A. M., C. L. W., R. H. H., S. E. K.], Surgery [C. J. Y.], Oncology [C. J. Y., R. H. H., S. E. K.], Cellular and Molecular Medicine [J. L.], and Public Health [G. M. P.], The Johns Hopkins Medical Institutions, Baltimore, Maryland 21205; the Division of Clinical and Molecular Genetics, Department of Medicine, Henry Ford Hospital, Detroit, Michigan 88202 [C. E. J.]; and the Department of Preventative Medicine/Public Health, Creighton University School of Medicine, Omaha, Nebraska 68178 [H. T. L.]
Germline mutations in BRCA2 predispose carriers to the development of breast, ovarian, and a variety of other cancers. The original localization of the BRCA2 gene was aided by its homozygous deletion in a pancreatic carcinoma; indeed, an excess of pancreatic carcinoma has been seen in some BRCA2 cancer families. To determine the involvement of BRCA2 in pancreatic carcinomas, we screened for BRCA2 alterations in an unselected panel of 41 adenocarcinomas of the pancreas (30 pancreatic adenocarcinoma xenografts and 11 pancreatic cancer cell lines). Of the 15 (27%) that had allelic loss at the BRCA2 locus, 4 (9.8%) had abnormalities in the second allele upon screening of the entire BRCA2 gene by in vitro synthesized protein assay. Three of the four mutations were considered germline in origin (7.3% overall; two were confirmed in normal tissue, and one was the 6174delT mutation from the pancreatic cancer cell line CAPAN-1, for which normal tissue was unavailable). The identification of two 6174delT mutations in this series prompted us to evaluate the prevalence of this mutation in an overlapping consecutive series of 245 patients who underwent pancreatoduodenectomy for adenocarcinoma of the pancreas. Sequence analysis of this limited region of the gene identified two additional mutations: (a) one additional germline 6174delT mutation (2 of 245, 0.8% overall); and (b) a second nearby germline 6158insT mutation. One of the patients with a germline mutation had a single relative with breast cancer, and another had a single relative with prostate cancer. None had a family history of pancreatic cancer.
The incidence of germline BRCA2 mutations in apparently sporadic pancreatic cancer may be at least as high as in breast or ovarian cancer. Our results suggest that some familial risks for carcinoma will be evident only through a population-based application of gene screening techniques because a low disease penetrance of the germline mutations in some families often evades clinical suspicion.
1 Supported by the Specialized Programs of Research Excellence for Gastrointestinal Cancer, NIH Grant CA62924, Nebraska State Cancer and Smoking Related Diseases grant [H. T. L.], and the University of Dublin [M. G.]. S. E. K. is a McDonnell Foundation Scholar.
2 To whom requests for reprints should be addressed, at the Department of Oncology, Johns Hopkins Medical Institutions, Baltimore, MD 21205-2196. Phone: (410) 614-3314; Fax: (410) 614-0671.
Received 8/30/96. Accepted 10/17/96.
This article has been cited by other articles:
|
|
 |
|
  A. Ashworth A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair J. Clin. Oncol., August 1, 2008; 26(22): 3785 - 3790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Hucl, C. Rago, E. Gallmeier, J. R. Brody, M. Gorospe, and S. E. Kern A Syngeneic Variance Library for Functional Annotation of Human Variation: Application to BRCA2 Cancer Res., July 1, 2008; 68(13): 5023 - 5030. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Evers, R. Drost, E. Schut, M. de Bruin, E. van der Burg, P. W.B. Derksen, H. Holstege, X. Liu, E. van Drunen, H. B. Beverloo, et al. Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clin. Cancer Res., June 15, 2008; 14(12): 3916 - 3925. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani, and A. P. Klein In Reply J. Clin. Oncol., November 20, 2007; 25(33): 5337 - 5338. [Full Text] [PDF]
|
|
|
|
|
|
T. Abe, N. Fukushima, K. Brune, C. Boehm, N. Sato, H. Matsubayashi, M. Canto, G. M. Petersen, R. H. Hruban, and M. Goggins Genome-Wide Allelotypes of Familial Pancreatic Adenocarcinomas and Familial and Sporadic Intraductal Papillary Mucinous Neoplasms Clin. Cancer Res., October 15, 2007; 13(20): 6019 - 6025. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Ji, F. C. Mei, J. Xie, and X. Cheng Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells J. Biol. Chem., May 11, 2007; 282(19): 14048 - 14055. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Greer and D. C Whitcomb Role of BRCA1 and BRCA2 mutations in pancreatic cancer Gut, May 1, 2007; 56(5): 601 - 605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Wang, S. Chen, K. A. Brune, R. H. Hruban, G. Parmigiani, and A. P. Klein PancPRO: Risk Assessment for Individuals With a Family History of Pancreatic Cancer J. Clin. Oncol., April 10, 2007; 25(11): 1417 - 1422. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gallmeier, T. Hucl, J. R. Brody, D. A. Dezentje, K. Tahir, J. Kasparkova, V. Brabec, K. E. Bachman, and S. E. Kern High-Throughput Screening Identifies Novel Agents Eliciting Hypersensitivity in Fanconi Pathway-Deficient Cancer Cells Cancer Res., March 1, 2007; 67(5): 2169 - 2177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. J. Couch, M. R. Johnson, K. G. Rabe, K. Brune, M. de Andrade, M. Goggins, H. Rothenmund, S. Gallinger, A. Klein, G. M. Petersen, et al. The Prevalence of BRCA2 Mutations in Familial Pancreatic Cancer Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 342 - 346. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Gallmeier and S. E. Kern Targeting Fanconi Anemia/BRCA2 Pathway Defects in Cancer: The Significance of Preclinical Pharmacogenomic Models Clin. Cancer Res., January 1, 2007; 13(1): 4 - 10. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Jimeno and M. Hidalgo Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. Mol. Cancer Ther., April 1, 2006; 5(4): 787 - 796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease Cancer Res., January 15, 2006; 66(2): 1208 - 1217. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. R. Payne and C. J. Kemp Tumor suppressor genetics Carcinogenesis, December 1, 2005; 26(12): 2031 - 2045. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. van der Heijden, J. R. Brody, D. A. Dezentje, E. Gallmeier, S. C. Cunningham, M. J. Swartz, A. M. DeMarzo, G. J. A. Offerhaus, W. H. Isacoff, R. H. Hruban, et al. In vivo Therapeutic Responses Contingent on Fanconi Anemia/BRCA2 Status of the Tumor Clin. Cancer Res., October 15, 2005; 11(20): 7508 - 7515. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X.-x. Tian, D. Rai, J. Li, C. Zou, Y. Bai, D. Wazer, V. Band, and Q. Gao BRCA2 Suppresses Cell Proliferation via Stabilizing MAGE-D1 Cancer Res., June 1, 2005; 65(11): 4747 - 4753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. A. Calin, F. Trapasso, M. Shimizu, C. D. Dumitru, S. Yendamuri, A. K. Godwin, M. Ferracin, G. Bernardi, D. Chatterjee, G. Baldassarre, et al. Familial Cancer Associated with a Polymorphism in ARLTS1 N. Engl. J. Med., April 21, 2005; 352(16): 1667 - 1676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Couch, M. R. Johnson, K. Rabe, L. Boardman, R. McWilliams, M. de Andrade, and G. Petersen Germ Line Fanconi Anemia Complementation Group C Mutations and Pancreatic Cancer Cancer Res., January 15, 2005; 65(2): 383 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Lorenzo Bermejo and K. Hemminki Risk of cancer at sites other than the breast in Swedish families eligible for BRCA1 or BRCA2 mutation testing Ann. Onc., December 1, 2004; 15(12): 1834 - 1841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C D Rogers, F J Couch, K Brune, S T Martin, J Philips, K M Murphy, G Petersen, C J Yeo, R H Hruban, and M Goggins Genetics of the FANCA gene in familial pancreatic cancer J. Med. Genet., December 1, 2004; 41(12): e126 - e126. [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Daniels, Y. Wang, M. Lee, and A. R. Venkitaraman Abnormal Cytokinesis in Cells Deficient in the Breast Cancer Susceptibility Protein BRCA2 Science, October 29, 2004; 306(5697): 876 - 879. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Schoenfeld, S. Apgar, G. Dolios, R. Wang, and S. A. Aaronson BRCA2 Is Ubiquitinated In Vivo and Interacts with USP11, a Deubiquitinating Enzyme That Exhibits Prosurvival Function in the Cellular Response to DNA Damage Mol. Cell. Biol., September 1, 2004; 24(17): 7444 - 7455. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S. Van der Heijden, J. R. Brody, E. Gallmeier, S. C. Cunningham, D. A. Dezentje, D. Shen, R. H. Hruban, and S. E. Kern Functional Defects in the Fanconi Anemia Pathway in Pancreatic Cancer Cells Am. J. Pathol., August 1, 2004; 165(2): 651 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hussain, J. B. Wilson, A. L. Medhurst, J. Hejna, E. Witt, S. Ananth, A. Davies, J.-Y. Masson, R. Moses, S. C. West, et al. Direct interaction of FANCD2 with BRCA2 in DNA damage response pathways Hum. Mol. Genet., June 15, 2004; 13(12): 1241 - 1248. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Liede, B. Y. Karlan, and S. A. Narod Cancer Risks for Male Carriers of Germline Mutations in BRCA1 or BRCA2: A Review of the Literature J. Clin. Oncol., February 15, 2004; 22(4): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. S. van der Heijden, R. H. Hruban, and S. E. Kern Reply Cancer Res., October 15, 2003; 63(20): 6999 - 7001. [Full Text] [PDF]
|
|
|
|
|
|
J-H Sng, A B Ali, S C Lee, D Zahar, J E L Wong, V Blake, A Sharif, G Cross, and P T C Iau BRCA1 c.2845insA is a recurring mutation with a founder effect in Singapore Malay women with early onset breast/ovarian cancer J. Med. Genet., October 1, 2003; 40(10): e117 - 117. [Full Text] [PDF]
|
|
|
|
|
|
M. S. van der Heijden, C. J. Yeo, R. H. Hruban, and S. E. Kern Fanconi Anemia Gene Mutations in Young-onset Pancreatic Cancer Cancer Res., May 15, 2003; 63(10): 2585 - 2588. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Iacobuzio-Donahue, A. Maitra, M. Olsen, A. W. Lowe, N. T. Van Heek, C. Rosty, K. Walter, N. Sato, A. Parker, R. Ashfaq, et al. Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays Am. J. Pathol., April 1, 2003; 162(4): 1151 - 1162. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Petersen and R. H. Hruban Familial Pancreatic Cancer: Where Are We in 2003? J Natl Cancer Inst, February 5, 2003; 95(3): 180 - 181. [Full Text] [PDF]
|
|
|
|
|
|
S. A. Hahn, B. Greenhalf, I. Ellis, M. Sina-Frey, H. Rieder, B. Korte, B. Gerdes, R. Kress, A. Ziegler, J. A. Raeburn, et al. BRCA2 Germline Mutations in Familial Pancreatic Carcinoma J Natl Cancer Inst, February 5, 2003; 95(3): 214 - 221. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Thompson, D. F. Easton, and the Breast Cancer Linkage Consortium Cancer Incidence in BRCA1 Mutation Carriers J Natl Cancer Inst, September 18, 2002; 94(18): 1358 - 1365. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. G. Howlett, T. Taniguchi, S. Olson, B. Cox, Q. Waisfisz, C. de Die-Smulders, N. Persky, M. Grompe, H. Joenje, G. Pals, et al. Biallelic Inactivation of BRCA2 in Fanconi Anemia Science, July 26, 2002; 297(5581): 606 - 609. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. C. Turner, M. Ottey, D. B. Zimonjic, M. Potoczek, W. W. Hauck, E. Pequignot, C. L. Keck-Waggoner, C. Sevignani, C. M. Aldaz, P. A. McCue, et al. The Fragile Histidine Triad/Common Chromosome Fragile Site 3B Locus and Repair-deficient Cancers Cancer Res., July 15, 2002; 62(14): 4054 - 4060. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Murphy, K. A. Brune, C. Griffin, J. E. Sollenberger, G. M. Petersen, R. Bansal, R. H. Hruban, and S. E. Kern Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17% Cancer Res., July 1, 2002; 62(13): 3789 - 3793. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F X Real, N Malats, G Lesca, M Porta, S Chopin, G M Lenoir, and O Sinilnikova Family history of cancer and germline BRCA2 mutations in sporadic exocrine pancreatic cancer Gut, May 1, 2002; 50(5): 653 - 657. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Hu, G. Li, W.-J. Li, C. Wang, A. M. Goldstein, Z.-Z. Tang, M. J. Roth, S. M. Dawsey, J. Huang, Q.-H. Wang, et al. Infrequent Mutation in the BRCA2 Gene in Esophageal Squamous Cell Carcinoma Clin. Cancer Res., April 1, 2002; 8(4): 1121 - 1126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-C. Wang, R. Shao, A. Y. Pao, S. Zhang, M.-C. Hung, and L.-K. Su Inhibition of Cancer Cell Growth by BRCA2 Cancer Res., March 1, 2002; 62(5): 1311 - 1314. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Anderson and J. E. Harris Selected Features of Nonendocrine Pancreatic Cancer Experimental Biology and Medicine, June 1, 2001; 226(6): 521 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Kern, R. Hruban, M. A. Hollingsworth, R. Brand, T. E. Adrian, E. Jaffee, and M. A. Tempero A White Paper: The Product of a Pancreas Cancer Think Tank Cancer Res., June 1, 2001; 61(12): 4923 - 4932. [Full Text] [PDF]
|
|
|
|
|
|
J T Bergthorsson, B Ejlertsen, J H Olsen, A Borg, K V Nielsen, R B Barkardottir, S Klausen, H T Mouridsen, K Winther, K Fenger, et al. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age J. Med. Genet., June 1, 2001; 38(6): 361 - 368. [Abstract] [Full Text]
|
|
|
|
|
|
H. Yamamoto, F. Itoh, H. Nakamura, H. Fukushima, S. Sasaki, M. Perucho, and K. Imai Genetic and Clinical Features of Human Pancreatic Ductal Adenocarcinomas with Widespread Microsatellite Instability Cancer Res., April 1, 2001; 61(7): 3139 - 3144. [Abstract] [Full Text]
|
|
|
|
|
|
A. C. Tersmette, G. M. Petersen, G. J. A. Offerhaus, F. C. Falatko, K. A. Brune, M. Goggins, E. Rozenblum, R. E. Wilentz, C. J. Yeo, J. L. Cameron, et al. Increased Risk of Incident Pancreatic Cancer Among First-degree Relatives of Patients with Familial Pancreatic Cancer Clin. Cancer Res., March 1, 2001; 7(3): 738 - 744. [Abstract] [Full Text]
|
|
|
|
|
|
E EFTHIMIOU, T CRNOGORAC-JURCEVIC, N R LEMOINE, and T A BRENTNALL Inherited predisposition to pancreatic cancer Gut, February 1, 2001; 48(2): 143 - 147. [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, Z.-C. Zeng, T.-A. Bui, S. J. DiBiase, W. Qin, F. Xia, S. N. Powell, and G. Iliakis Nonhomologous End-Joining of Ionizing Radiation-induced DNA Double-Stranded Breaks in Human Tumor Cells Deficient in BRCA1 or BRCA2 Cancer Res., January 1, 2001; 61(1): 270 - 277. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. Gerdes, A. Ziegler, A. Ramaswamy, A. Wild, P. Langer, and D. K Bartsch Multiple primaries in pancreatic cancer patients: indicator of a genetic predisposition? Int. J. Epidemiol., December 1, 2000; 29(6): 999 - 1003. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Le Page, V. Randrianarison, D. Marot, J. Cabannes, M. Perricaudet, J. Feunteun, and A. Sarasin BRCA1 and BRCA2 Are Necessary for the Transcription-Coupled Repair of the Oxidative 8-Oxoguanine Lesion in Human Cells Cancer Res., October 1, 2000; 60(19): 5548 - 5552. [Abstract] [Full Text]
|
|
|
|
|
|
R. H. Hruban, M. Goggins, J. Parsons, and S. E. Kern Progression Model for Pancreatic Cancer Clin. Cancer Res., August 1, 2000; 6(8): 2969 - 2972. [Full Text]
|
|
|
|
 |
|
 V. P.C.C. Yu, M. Koehler, C. Steinlein, M. Schmid, L. A. Hanakahi, A. J. van Gool, S. C. West, and A. R. Venkitaraman Gross chromosomal rearrangements and genetic exchange between nonhomologous chromosomes following BRCA2 inactivation Genes & Dev., June 1, 2000; 14(11): 1400 - 1406. [Abstract] [Full Text]
|
|
|
|
|
|
R. E. Wilentz, M. Goggins, M. Redston, V. A. Marcus, N. V. Adsay, T. A. Sohn, S. S. Kadkol, C. J. Yeo, M. Choti, M. Zahurak, et al. Genetic, Immunohistochemical, and Clinical Features of Medullary Carcinoma of the Pancreas : A Newly Described and Characterized Entity Am. J. Pathol., May 1, 2000; 156(5): 1641 - 1651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Goggins, R. H. Hruban, and S. E. Kern BRCA2 Is Inactivated Late in the Development of Pancreatic Intraepithelial Neoplasia : Evidence and Implications Am. J. Pathol., May 1, 2000; 156(5): 1767 - 1771. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Wilentz, C. A. Iacobuzio-Donahue, P. Argani, D. M. McCarthy, J. L. Parsons, C. J. Yeo, S. E. Kern, and R. H. Hruban Loss of Expression of Dpc4 in Pancreatic Intraepithelial Neoplasia: Evidence That DPC4 Inactivation Occurs Late in Neoplastic Progression Cancer Res., April 1, 2000; 60(7): 2002 - 2006. [Abstract] [Full Text]
|
|
|
|
|
|
C. S. Sinclair, R. Berry, D. Schaid, S. N. Thibodeau, and F. J. Couch BRCA1 and BRCA2 Have a Limited Role in Familial Prostate Cancer Cancer Res., March 1, 2000; 60(5): 1371 - 1375. [Abstract] [Full Text]
|
|
|
|
|
|
G. Lal, G. Liu, B. Schmocker, P. Kaurah, H. Ozcelik, S. A. Narod, M. Redston, and S. Gallinger Inherited Predisposition to Pancreatic Adenocarcinoma: Role of Family History and Germ-Line p16, BRCA1, and BRCA2 Mutations Cancer Res., January 1, 2000; 60(2): 409 - 416. [Abstract] [Full Text]
|
|
|
|
|
|
D. Cortez, Y. Wang, J. Qin, and S. J. Elledge Requirement of ATM-Dependent Phosphorylation of Brca1 in the DNA Damage Response to Double-Strand Breaks Science, November 5, 1999; 286(5442): 1162 - 1166. [Abstract] [Full Text]
|
|
|
|
|
|
S. Ohnami, N. Matsumoto, M. Nakano, K. Aoki, K. Nagasaki, T. Sugimura, M. Terada, and T. Yoshida Identification of Genes Showing Differential Expression in Antisense K-ras-transduced Pancreatic Cancer Cells with Suppressed Tumorigenicity Cancer Res., November 1, 1999; 59(21): 5565 - 5571. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Breast Cancer Linkage Consortium Cancer Risks in BRCA2 Mutation Carriers J Natl Cancer Inst, August 4, 1999; 91(15): 1310 - 1316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S.-S. F. Yuan, S.-Y. Lee, G. Chen, M. Song, G. E. Tomlinson, and E. Y-H. P. Lee BRCA2 Is Required for Ionizing Radiation-induced Assembly of Rad51 Complex in Vivo Cancer Res., August 1, 1999; 59(15): 3547 - 3551. [Abstract] [Full Text] [PDF]
|
|
|
